Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Lilly adds to obesity drug production push with $3B investment
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana and will help make more injectable drugs like fast-selling Zepbound.
U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible, and alongside a specialized diet.
Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory it bought early this year, and the investment will help meet growing demand for injectable products like it
Eli Lilly To Invest $3B To Expand Plant To Meet Surge In Demand For Weight Loss Drugs
Eli Lilly announced a $3 billion expansion of a manufacturing facility the drugmake r bought earlier this year in Wisconsin to ramp up production of its diabetes and weight-loss drugs. The pharmaceutical giant said it will expand the plant in Kenosha County,
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
Eli Lilly LLY recently announced its plans to spend $3 billion to expand the manufacturing facility in Wisconsin that was acquired earlier this year from Nexus Pharmaceuticals. Management expects to start construction on this expansion next year.
1d
on MSN
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
Most of Israel "Izzy" Englander's favorite stocks these days are technology leaders. At least that's the conclusion you'd ...
STAT
2d
Pharmalittle: We’re reading about U.K. restricting Lilly’s obesity drug, pharma layoffs, and more
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
2d
Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
10d
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
FiercePharma
3d
For first phase of Mounjaro's obesity rollout in England, only a limited number of patients will have access
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
11d
on MSN
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
3d
Britain drug-cost watchdog says it will recommend Lilly obesity drug
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
9d
on MSN
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
BioPharma Dive
3d
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
4d
on MSN
Altimmune CEO on what’s next for its experimental obesity drug
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback